The stock of Janux Therapeutics Inc (JANX) has seen a -5.03% decrease in the past week, with a -8.27% drop in the past month, and a -53.59% decrease in the past quarter. The volatility ratio for the week is 10.99%, and the volatility levels for the past 30 days are at 6.83% for JANX.. The simple moving average for the past 20 days is -7.02% for JANX’s stock, with a -39.17% simple moving average for the past 200 days.
Is It Worth Investing in Janux Therapeutics Inc (NASDAQ: JANX) Right Now?
JANX has 36-month beta value of 3.09. Analysts have mixed views on the stock, with 12 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for JANX is 49.57M, and currently, short sellers hold a 21.18% ratio of that float. The average trading volume of JANX on April 10, 2025 was 933.44K shares.
JANX) stock’s latest price update
Janux Therapeutics Inc (NASDAQ: JANX) has experienced a rise in its stock price by 12.78 compared to its previous closing price of 23.79. However, the company has seen a fall of -5.03% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-05 that Janux Therapeutics’ lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company’s strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates.
Analysts’ Opinion of JANX
Many brokerage firms have already submitted their reports for JANX stocks, with H.C. Wainwright repeating the rating for JANX by listing it as a “Buy.” The predicted price for JANX in the upcoming period, according to H.C. Wainwright is $70 based on the research report published on December 03, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see JANX reach a price target of $100, previously predicting the price at $82. The rating they have provided for JANX stocks is “Buy” according to the report published on December 03rd, 2024.
Leerink Partners gave a rating of “Outperform” to JANX, setting the target price at $79 in the report published on November 22nd of the previous year.
JANX Trading at -19.07% from the 50-Day Moving Average
After a stumble in the market that brought JANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.59% of loss for the given period.
Volatility was left at 6.83%, however, over the last 30 days, the volatility rate increased by 10.99%, as shares sank -15.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.94% lower at present.
During the last 5 trading sessions, JANX fell by -5.03%, which changed the moving average for the period of 200-days by -34.50% in comparison to the 20-day moving average, which settled at $28.86. In addition, Janux Therapeutics Inc saw -49.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JANX starting from RA CAPITAL MANAGEMENT, L.P., who purchase 372,093 shares at the price of $30.78 back on Mar 06 ’25. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 10,031,081 shares of Janux Therapeutics Inc, valued at $11,453,023 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the Director of Janux Therapeutics Inc, purchase 341,742 shares at $30.64 during a trade that took place back on Mar 05 ’25, which means that RA CAPITAL MANAGEMENT, L.P. is holding 9,658,988 shares at $10,471,352 based on the most recent closing price.
Stock Fundamentals for JANX
Current profitability levels for the company are sitting at:
- -9.34 for the present operating margin
- 0.9 for the gross margin
The net margin for Janux Therapeutics Inc stands at -6.52. The total capital return value is set at -0.09. Equity return is now at value -10.09, with -9.57 for asset returns.
Based on Janux Therapeutics Inc (JANX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -1.9.
Currently, EBITDA for the company is -98.85 million with net debt to EBITDA at 4.21. When we switch over and look at the enterprise to sales, we see a ratio of 111.28. The receivables turnover for the company is 1.97for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 59.21.
Conclusion
To put it simply, Janux Therapeutics Inc (JANX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
